Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
07 nov. 2022 18h15 HE
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (November 7, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics...
Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
11 oct. 2022 16h05 HE
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (October 11, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...
Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors
26 sept. 2022 06h00 HE
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (September 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology...
Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference
16 sept. 2022 06h00 HE
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (September 16, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology...
Allarity Therapeutics Announces Appointment of New Auditor
12 sept. 2022 16h10 HE
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (September 12, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel...
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
26 août 2022 16h30 HE
|
Allarity Therapeutics, Inc.
Press release Cambridge, MA U.S.A. (August 26, 2022) — Allarity Therapeutics, Inc. (Nasdaq: ALLR) (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel...
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
02 août 2022 06h00 HE
|
Allarity Therapeutics, Inc.
New strategy aligns with ongoing shift in oncology standard-of-caretowards combination therapies Combination therapy focus expected to improve the Company’s future funding and commercial...
Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D.
11 juil. 2022 07h00 HE
|
Allarity Therapeutics, Inc.
Interim CEO James G. Cullem, J.D. and Co-Founder Thomas Jensen also joining the Board Press ReleaseCambridge, MA, U.S.A. (July 11, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the...
Allarity Therapeutics Announces Executive Leadership Transition
29 juin 2022 16h01 HE
|
Allarity Therapeutics, Inc.
Board Appoints James G. Cullem, J.D., to Interim Chief Executive Officer,Joan Y. Brown, CPA, to Interim Chief Financial Officer Press release Cambridge, MA, U.S.A. (June 29, 2022) — Allarity...
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.
15 juin 2022 09h25 HE
|
Allarity Therapeutics, Inc.
Cambridge, MA U.S.A. (June 15, 2022) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with...